Cue Biopharma, Inc. (NASDAQ:CUE – Get Free Report) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totaling 288,887 shares, a decline of 96.2% from the April 15th total of 7,541,901 shares. Based on an average trading volume of 533,660 shares, the short-interest ratio is currently 0.5 days. Approximately 9.1% of the company’s stock are short sold.
Institutional Investors Weigh In On Cue Biopharma
Institutional investors and hedge funds have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. lifted its position in Cue Biopharma by 730.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after acquiring an additional 73,000 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Cue Biopharma in the 3rd quarter worth $62,000. Stifel Financial Corp increased its holdings in shares of Cue Biopharma by 25.4% in the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc raised its stake in shares of Cue Biopharma by 1,231.2% in the fourth quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after purchasing an additional 407,568 shares during the last quarter. Finally, Boothbay Fund Management LLC purchased a new position in shares of Cue Biopharma in the third quarter worth $439,000. Institutional investors own 35.04% of the company’s stock.
Cue Biopharma Price Performance
Cue Biopharma stock traded up $0.21 during mid-day trading on Wednesday, reaching $29.47. The stock had a trading volume of 132,943 shares, compared to its average volume of 521,442. Cue Biopharma has a one year low of $4.97 and a one year high of $41.42. The company has a 50-day moving average price of $240.81 and a two-hundred day moving average price of $346.09. The company has a market capitalization of $96.07 million, a price-to-earnings ratio of -3.07 and a beta of 2.37.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Cue Biopharma
Cue Biopharma Company Profile
Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.
Featured Stories
- Five stocks we like better than Cue Biopharma
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
